SPP100 Dose Finding Study in Japan

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy of SPP100 in lowering blood pressure in patients with essential hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis

Criteria

Inclusion Criteria:

1. Mild to moderate essential hypertension

2. Age: ≥20 years old and <80 years old (at time informed consent obtained)

3. Sex: N/A

4. Admission status: Outpatient

Exclusion Criteria:

1. Pregnant women, lactating women, potentially pregnant women, or women who wish to become pregnant

2. Patients having a mean sitting diastolic blood pressure of ≥110 mmHg and/or a mean sitting systolic blood pressure of ≥180 mmHg at either Visit 2 or 3

3. Patients with secondary hypertension as a complication or patients suspected of having secondary hypertension(due to aortic coarctation, primary aldosteronism, coarctation of renal artery, renal hypertension

4. Patients suspected of having malignant hypertension